In this Article the Competing interests statement inadvertently omitted a statement for M.T.L. and L.E.D. The competing financial interests for M.T.L. should have read: ‘M.T.L. is a founder and limited partner in StemMed Ltd. and a manager in StemMed Holdings, its general partner. He is a founder and equity stakeholder in Tvardi Theraeutics Inc. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to M.T.L.’. The competing financial interests for L.E.D. should have read, ‘L.E.D. is a compensated employee of StemMed Ltd’. The PDF and HTML versions of the Article have been corrected.

Original languageEnglish
Article number294
JournalNature communications
Issue number1
StatePublished - Dec 2022


Dive into the research topics of 'Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)'. Together they form a unique fingerprint.

Cite this